The Approval of Revlimid for Patients with Relapsed or Refractory MCL
Andre Goy, MD, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL)
Andre Goy, MD, chairman, director and chief of Lymphoma at John Theurer Cancer Center, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL).
Goy says this is the first time that lenalidomide is approved in a lymphoma and is only the second drug approved for relapsed or refractory MCL. Lenalidomide was recently approved for multiple myeloma.
There was evidence that the drug showed activity in lymphoma recently, Goy says, but it took time to generate data to prove that to be true.
A phase II trial focused on 134 patients who had failed standard of care for relapsed or refractory MCL, Goy says. In the study, 29% of patients responded to treatment while about 8% demonstrated complete response. The duration of response for these patients was close to 16 months, Goy says, demonstrating an improvement over chemotherapy.
Clinical Pearls
- Revlimid received expanded approval as treatment for relapsed or refractory mantle cell lymphoma
- Twenty nine percent of patients in a phase II trial responded to Revlimid and close to 8% showed complete response
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
